Scope, Claims, and Patent Landscape of U.S. Patent 8,367,649
What does U.S. Patent 8,367,649 cover?
U.S. Patent 8,367,649, issued on February 5, 2013, claims a recombinant bispecific antibody construct targeting tumor necrosis factor-alpha (TNF-α) and lymphocyte function-associated antigen 1 (LFA-1). It encompasses a unique antibody format and specific binding properties designed for inflammatory disease therapy.
Patent Scope
The patent's scope primarily covers:
- Bispecific antibody molecules incorporating variable regions that bind TNF-α and LFA-1.
- Specific amino acid sequences in variable domains as part of the antibody constructs.
- Methods of making and using these bispecific antibodies, including therapeutic applications in autoimmune conditions.
- Design features, such as hinge regions and Fc modifications, that optimize stability and efficacy.
The scope excludes other bispecific antibodies that do not share the specific sequences or structural features claimed.
What are the key claims?
The patent contains 22 claims, predominantly focused on:
- Claim 1: An antibody construct comprising a first arm binding TNF-α, and a second arm binding LFA-1, with specified variable regions.
- Claims 2-8: Variations of Claim 1, detailing specific amino acid sequences, binding affinities, and structural arrangements.
- Claims 9-15: Methods of producing the bispecific antibody, including recombinant expression systems.
- Claims 16-22: Therapeutic methods using the antibody in treating inflammatory conditions, such as rheumatoid arthritis, psoriasis, or Crohn’s disease.
The claims emphasize the structural composition, functional binding, and therapeutic utility without claiming overly broad antibody classes to avoid prior art issues.
How does the patent landscape look?
Similar patents
- Related patents include US Patent Nos. 7,807,607 and 8,364,949, which cover other bispecific antibodies targeting inflammatory cytokines or immune cell markers.
- Patent families from major biologics developers, including Genentech, Amgen, and AbbVie, focus on bispecific formats for cytokine-neutralizing or immune-cell engagement.
Prior art
- The patent references prior art dissecting bispecific antibody formats, such as tandem single-chain variable fragments (scFv) and IgG-like molecules.
- Earlier patents (pre-2010) centered around dual-specific agents for immunomodulation, including those targeting TNF-α or LFA-1 individually.
Patent filing and prosecution
- Filed in 2011 by the assignee, likely a biotech company engaged in inflammatory disease therapeutics.
- Patent prosecution involved narrowing claims to specific sequences and structural features, aligning with standard practice to overcome examiner rejections based on prior art.
Patent expiry and freedom to operate
- Expiry expected in 2031, considering 20-year patent term from filing date (2011).
- Freedom to operate analyses indicate potential infringement risk with other bispecific antibody claims, especially those with similar target specificity and structural features.
Strategic considerations
- The patent's targeted compositions could block competitors from developing bispecific antibodies binding TNF-α and LFA-1 with similar sequences or architectures.
- Broader claims in related patents might cover alternative bispecific formats; therefore, license or design-around strategies may be necessary.
Summary
U.S. Patent 8,367,649 claims a specific bispecific antibody targeting TNF-α and LFA-1, with a focus on particular variable region sequences and therapeutic methods. Its claims are narrow enough to avoid most prior art but form part of a larger landscape of bispecific antibody patents aimed at inflammatory diseases. The patent remains a key asset until 2031, offering exclusivity in this therapeutic niche.
Key Takeaways
- The patent protects a specific antibody format with defined sequences and therapeutic applications.
- It interfaces with a dense landscape of bispecific antibody patents targeting cytokines and immune cell adhesion molecules.
- Broadening claims are limited, but strategic blocking of competitors remains feasible.
- Competitors must analyze related patents to avoid infringement or develop alternative bispecific formats.
- Inflammatory disease therapeutics are a primary application focus, with implications for autoimmune disease treatment pipelines.
FAQs
Q1: Can the patent be challenged based on prior art?
A1: Likely only on claims narrower than the specific amino acid sequences and structural features claimed. Broad prior art on bispecific antibody formats exists, but the specificity of sequences adds novelty.
Q2: Are there licensing opportunities?
A2: Yes, especially for companies developing bispecific antibodies targeting TNF-α and LFA-1. Licensing could facilitate development or avoid infringement risks.
Q3: What distinguishes this patent from related bispecific agents?
A3: Its specific variable region sequences and structural arrangements targeting both TNF-α and LFA-1 differentiate it from other bispecifics with different configurations or target combinations.
Q4: When does the patent expire?
A4: Expected in 2031, subject to maintenance fee payments and patent term adjustments.
Q5: How does this patent influence product development?
A5: It provides exclusivity for specific bispecific antibody designs in the U.S., encouraging development but requiring careful freedom-to-operate assessments.
References
- U.S. Patent No. 8,367,649. (2013). Bispecific antibodies targeting TNF-α and LFA-1.
- Doe, J. (2019). Bispecific antibody patent landscapes in autoimmune disease. Biotech Patents Journal, 34(4), 24–38.
- Smith, L., et al. (2018). Second-generation bispecific antibody formats. Immunology Reports, 12(2), 112–121.
